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Upstream transcription factor 1 (USF1) is a ubiquitously expressed transcription factor controlling several critical genes
in lipid and glucose metabolism. Of some 40 genes regulated by USF1, several are involved in the molecular
pathogenesis of cardiovascular disease (CVD). Although the USF1 gene has been shown to have a critical role in the
etiology of familial combined hyperlipidemia, which predisposes to early CVD, the gene’s potential role as a risk factor
for CVD events at the population level has not been established. Here we report the results from a prospective genetic–
epidemiological study of the association between the USF1 variants, CVD, and mortality in two large Finnish cohorts.
Haplotype-tagging single nucleotide polymorphisms exposing all common allelic variants of USF1 were genotyped in a
prospective case-cohort design with two distinct cohorts followed up during 1992–2001 and 1997–2003. The total
number of follow-up years was 112,435 in 14,140 individuals, of which 2,225 were selected for genotyping based on
the case-cohort study strategy. After adjustment for conventional risk factors, we observed an association of USF1 with
CVD and mortality among females. In combined analysis of the two cohorts, female carriers of a USF1 risk haplotype
had a 2-fold risk of a CVD event (hazard ratio [HR] 2.02; 95% confidence interval [CI] 1.16–3.53; p ¼ 0.01) and an
increased risk of all-cause mortality (HR 2.52; 95% CI 1.46–4.35; p ¼ 0.0009). A putative protective haplotype of USF1
was also identified. Our study shows how a gene identified in exceptional families proves to be important also at the
population level, implying that allelic variants of USF1 significantly influence the prospective risk of CVD and even all-
cause mortality in females.
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Introduction
The upstream transcription factor 1 (USF1) gene encoding
USF1, a ubiquitously expressed transcription factor control-
ling some 40 genes [1], based on its function is an attractive
candidate gene for cardiovascular disease (CVD). Initially this
gene was identiﬁed as the ﬁrst familial combined hyper-
lipidemia (FCHL) gene in rare Finnish pedigrees with
multiple affected individuals having a greatly increased risk
for CVD [2]. This ﬁnding was rapidly replicated in Mexican
families [3], and since then USF1 has also been associated with
the metabolic syndrome and type II diabetes in study samples
ascertained for these traits [4].
Thus, the combined evidence indicates a role for USF1 in
the molecular background of hyperlipidemias, yet the direct
contribution of the USF1 gene to CVD at the population level
has not been addressed. To adequately evaluate the impact of
a gene or a risk allele on the disease risk at the population
level requires a prospective follow-up study, a golden stand-
ard in traditional epidemiology, in which risk factor(s) are
measured at the beginning of the follow-up, and the
diagnostic endpoints are registered as the study proceeds.
We have in this study used two unique cohorts from Finland,
the population in which the USF1 gene was identiﬁed as an
FCHL gene, to address the general signiﬁcance of the USF1
gene as a risk factor for CVD in population-based, prospec-
tive manner. We evaluated allelic variants of the USF1 gene by
genotyping haplotype-tagging single-nucleotide polymor-
phisms (htSNPs) of the USF1 locus and assessing their
association with CVD events in the two prospective cohorts.
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PLoS Genetics | www.plosgenetics.org May 2006 | Volume 2 | Issue 5 | e69 0672Speciﬁc alleles of the USF1 gene proved to modify the CVD
risk in women and to contribute both to CVD and mortality
at the population level.
Results
Figure 1 shows characteristics of the two FINRISK [5]
cohorts. The number of individuals recruited in the FINRISK-
97 cohort was larger than in the FINRISK-92 at the baseline
of the study. However, since the follow-up time was shorter
for the FINRISK-97, the number of person-years was smaller
for this younger cohort (54,577 person-years in FINRISK-97
versus 57,858 person-years in FINRISK-92). We selected
incident cases and random subcohorts from the FINRISK
cohorts for genotyping of six htSNPs as shown in Figure 1 and
Tables 1 and 2.
The genotype frequencies of all six SNPs followed Hardy-
Weinberg equilibrium at the 0.05 level among the subcohorts
of the FINRISK study samples. The linkage disequilibrium
(LD) structure of the USF1 gene and haplotype tagging
properties of the genotyped SNPs were examined combining
the two subcohorts. The selected six htSNPs captured the
common haplotypes of USF1 well (all haplotypes with
frequency . 4% in SeattleSNPs database (Figure 2) [6]).
Due to the high LD across the USF1 gene locus (D9 0.995–
1.000 between all SNP pairs), only ﬁve haplotypes were
observed. Importantly, based on the distribution of the SNP
alleles into various haplotypes, it was evident that the SNP
alleles unequivocally speciﬁed haplotypes; thus, the selected
SNPs truly represented htSNPs for this gene.
The minor allele frequencies of the USF1 SNPs varied from
11% to 41% in the subcohorts (Table 3). In both FINRISK
cohorts, SNP rs2073658 showed a difference in the minor
allele frequency between the female incident CVD cases and
the subcohort free of CVD (p ¼ 0.05 for FINRISK-92 and
FINRISK-97 combined). This SNP represents the variant
previously associated with FCHL in Finnish pedigrees, and in
both cohorts the minor allele seemed to be more prevalent
among incident female CVD cases when compared to
subcohort females free of CVD. For another SNP,
rs2774279, located 6.8 kb 59 from rs2073658, the minor allele
frequency was higher among the subcohort females free of
CVD than among incident female CVD cases (p ¼ 0.03 for
FINRISK-92 and FINRISK-97 combined), especially in the
FINRISK-92 (p¼0.008) study sample with a longer follow-up.
The minor alleles of these two SNPs both tag one haplotype
of USF1. The minor allele of rs2073658 tags the most common
USF1 haplotype, and the minor allele of rs2774279 tags the
second most common haplotype of USF1 (Figure 2).
Cox proportional hazards regression analysis measuring
time-to-event was used to estimate the risk of an incident
CVD event or mortality during the follow-up period in
relation to the USF1 SNPs. Allele-speciﬁc hazard ratios for
the six SNPs tested are shown in Table 4 for analyses testing
the two FINRISK cohorts separately and for analyses pooling
the cohorts. Analysis of the previously analyzed SNP
rs2073658 [1–4,7,8] revealed an increased risk of incident
CVD (HR 2.02; 95% conﬁdence interval [CI] 1.16–3.53; p ¼
0.01) and all-cause mortality (HR 2.52; 95% CI 1.46–4.35; p ¼
0.0009) for carriers of T-allele among females when compared
to noncarriers of the allele. The increased risk was evident
especially among the FINRISK-97 females; however, the
hazard ratio was increased also among the FINRISK-92
females, although it did not reach statistical signiﬁcance.
The second SNP showing a difference in the minor allele
frequency between incident cases and subcohort free of CVD,
rs2774279, was also associated with increased risk of incident
CVD and mortality in time-to-event analysis. Risk of mortal-
ity was increased among the female carriers of the G-allele of
rs2774279 (HR 4.43; 95% CI 1.58–12.40; p¼0.005). Again, the
increased risk was observed especially among the FINRISK-97
females. Also, the risk of CVD was higher among female
carriers of the rs2774279 G-allele (HR 4.01; 95% CI 1.30–
12.39; p ¼ 0.02), and the effect of the SNP was observed in
Figure 1. A Description of the FINRISK 1992 and 1997 Cohorts
Compared to FINRISK-92, the FINRISK-97 cohort includes an additional
sample of individuals aged 65–74 y. Numbers for this additional sample
are described at the right-hand side for each endpoint. Persons
examined refers to cohort individuals for whom information on smoking,
blood pressure, cholesterol, and DNA, as well as consent for the use of
DNA to study CHD and stroke, were available. Subcohorts are stratified
random samples of the original cohorts including also cases. Mortality
cases show total mortality, including also those who died from CHD or
stroke. Thus, numbers in the boxes of subcohorts and outcome events
are not mutually exclusive (see Table 1). F, females; M, males.
DOI: 10.1371/journal.pgen.0020069.g001
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Synopsis
Better characterization of molecular events resulting in cardiovas-
cular disease (CVD) requires elucidation of genetic background of
CVD. After a CVD candidate gene is identified in family-based
studies or case-control studies, population-based prospective
studies are needed to demonstrate any potential impact of allelic
variants on the CVD risk at the population level. This study addresses
the role of different alleles of the upstream transcription factor 1
(USF1) gene, encoding a transcription factor and originally
associated with familial combined hyperlipidemia in rare families
with multiple affected individuals. The product of USF1 regulates
numerous genes of lipid and glucose metabolism, and the authors
show in large population cohorts that specific alleles of USF1 are
associated with the risk of CVD and all-cause mortality among
females. The study implies an interesting female-specific risk effect,
and should stimulate additional studies of the sex-specific CVD risk
genes in different populations.both FINRISK cohorts. Among FINRISK-97 females, the
effect of SNP rs2774279 was visible when comparing carriers
of the G-allele with others (HR 15.38; 95% CI 2.49–94.87; p ¼
0.003). Interestingly, among the FINRISK-92 females, the
effect of SNP rs2774279 was observed when comparing
carriers of the A-allele with others (HR 0.33; 95% CI 0.13–
0.85; p ¼ 0.02).
No signiﬁcant associations with the risk of an incident CVD
event or mortality were observed among males in combined
analysis of the two cohorts. Among FINRISK-92 males, a
suggestive association was obtained for risk of mortality and
the T-allele of SNP rs2516839 (HR 1.83; 95% CI 1.00–3.36; p¼
0.05), and including FINRISK-92 females to the analysis
further strengthened the results (HR 1.86; 95% CI 1.13–3.05; p
¼ 0.01). Otherwise, the only association seen in the pooled
analyses of males and females was a decreased risk of CVD
(HR 0.53; 95% CI 0.30–0.95; p¼0.03) observed for carriers of
the rs2073658 C-allele when compared to noncarriers of the
allele among the FINRISK-92 cohort.
We used permutation analysis to determine a critical p-
value for 5% level of signiﬁcance corrected for multiple
testing for our results; we permuted the genotype while
retaining the phenotype data and repeated the same analyses
that were performed with the actual dataset and repeated this
procedure 1,000 times. In the time-to-event analyses where
FINRISK-92 males and females were pooled together,
permutation analysis suggested a critical p-value of 0.005
for a 5% level of signiﬁcance for both CVD risk and mortality
risk. All other critical p-values obtained from permutation
analysis can be seen in Table 4.
Table 1. Numbers of Study Subjects in the Random Subcohort and with Different Endpoint Events in FINRISK-92 and FINRISK-97
Cohorts
Cohort Sex Incident
CVD
a
Death
(Any Cause)
Subcohort Incident CVD
and Death
Incident CVD
and Subcohort
Death and
Subcohort
Incident
CVD, Death,
and Subcohort
FINRISK-92 Males 170 188 286 48 37 34 12
Females 86 94 114 10 7 9 3
FINRISK-97 Males 204 242 304 54 23 35 7
Females 68 86 72 24 5 8 3
aIncident CHD and incident ischemic stroke combined; the first one (either CHD or stroke event) was used in the analyses. Altogether 21 out of the 528 CVD cases had both incident CHD
and incident ischemic stroke during the follow-up period. Two were FR97 females, 11 were FR97 males, and eight were FR92 males.
DOI: 10.1371/journal.pgen.0020069.t001
Table 2. Baseline Characteristics of Cardiovascular Cases and Subcohort
Characteristic FR92 Males FR92 Females FR97 Males FR97 Females FR92þFR97 Males FR92þFR97 Females
CVD
Cases
a
Sub-
cohort
b
CVD
Cases
a
Sub-
cohort
b
CVD
Cases
a
Sub-
cohort
b
CVD
Cases
a
Sub-
cohort
b
CVD
Cases
a
Sub-
cohort
b
CVD
Cases
a
Sub-
cohort
b
Number of
subjects
170 220 86 104 204 231 68 71 374 451 154 175
Smoking
c 67 (39) 54 (25) 14 (16) 10 (10) 55 (27) 54 (23) 14 (21) 8 (11) 122 (33) 108 (24) 28 (18) 18 (10)
Diabetes
c 16 (9) 10 (5) 13 (15) 4 (4) 28 (14) 13 (6) 12 (18) 5 (7) 44 (12) 23 (5) 25 (16) 9 (5)
Hypertension
c 120 (71) 120 (55) 68 (79) 66 (63) 153 (75) 151 (65) 46 (68) 53 (75) 273 (73) 271 (60) 114 (74) 119 (68)
Age at baseline
(years)
d
54.2 (7.7) 52.8 (9.1) 55.0 (8.0) 55.9 (6.7) 61.9 (8.7) 59.9 (10.2) 62.8 (7.4) 63.1 (7.5) 58.4 (9.1) 56.4 (10.3) 58.5 (8.6) 58.8 (7.9)
Age at first CVD
event (years)
d
59.5 (7.4) NA 60.6 (8.5) NA 65.5 (8.9) NA 66.3 (7.5) NA 62.8 (8.8) NA 63.1 (8.6) NA
Total cholesterol
(mmol/l)
d,e
6.28 (1.11) 5.87 (0.99) 6.06 (1.30) 5.96 (0.98) 5.79 (1.03) 5.66 (0.97) 6.05 (0.93) 6.00 (1.11) 6.02 (1.09) 5.76 (0.99) 6.06 (1.15) 5.98 (1.03)
HDL cholesterol
(mmol/l)
d,e
1.17 (0.32) 1.27 (0.35) 1.35 (0.38) 1.58 (0.35) 1.17 (0.28) 1.26 (0.32) 1.41 (0.37) 1.53 (0.37) 1.17 (0.30) 1.27 (0.34) 1.37 (0.38) 1.56 (0.36)
Non-HDL
cholesterol
d,e
5.12 (1.13) 4.59 (1.02) 4.72 (1.36) 4.37 (1.02) 4.62 (1.00) 4.39 (0.97) 4.64 (0.95) 4.47 (1.05) 4.85 (1.09) 4.49 (1.00) 4.68 (1.19) 4.41 (1.03)
Triglycerides
d,e 2.12 (1.17) 1.78 (0.99) 1.85 (1.14) 1.32 (0.76) 1.89 (1.09) 1.69 (1.05) 1.78 (0.92) 1.55 (0.86) 2.00 (1.14) 1.74 (1.02) 1.82 (1.05) 1.41 (0.81)
Waist-to-hip
ratio
d
0.97 (0.06) 0.95 (0.07) 0.84 (0.07) 0.80 (0.06) 0.97 (0.06) 0.94 (0.06) 0.84 (0.07) 0.83 (0.07) 0.97 (0.06) 0.95 (0.06) 0.84 (0.07) 0.81 (0.06)
BMI (kg/m
2)
d 28.6 (3.9) 27.4 (3.9) 29.3 (5.2) 26.9 (4.7) 28.6 (3.5) 27.5 (3.9) 29.3 (4.5) 27.9 (4.4) 28.6 (3.6) 27.5 (3.9) 29.3 (4.9) 27.3 (4.6)
aIncident CVD cases (includes incident CHD cases and incident ischemic stroke cases).
bSubcohort members without CVD at baseline or during the follow-up.
cData are given as number (%).
dData are given as mean (SD).
ePersons with lipid-lowering medication at baseline (n ¼ 44) were excluded from calculations.
FR, FINRISK; NA, not applicable.
DOI: 10.1371/journal.pgen.0020069.t002
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USF1 in a Prospective StudyIn our age-stratiﬁed study samples, the average age of the
onset of CVD was about the same for males and females
(Table 2). Since females generally have their ﬁrst CVD event
at an older age than men, we tested whether the observed sex
difference was primarily due to a possible difference in
relative age at event for males and females in our study
sample. The time-to-event analysis combined for the two
cohorts was repeated for males who had their ﬁrst CVD event
early (before age 55; n¼70), but no associations with CVD or
mortality were observed (unpublished data).
The time-to-event results of individual htSNPs suggested
that the rs2073658 T-allele and rs2774279 G-allele increase
the risk of CVD and mortality among females. From the USF1
haplotypes it was obvious that the rs2073658 T-allele was
present only in haplotype CTCTAG (population frequency
34%) (Figure 2), thus specifying it as a risk-increasing
haplotype. The rs2774279 G-allele was present in all other
haplotypes but the CCCTAA haplotype (population fre-
quency 29%), thus implying a protective role for this
haplotype. We wanted to investigate more closely how the
carriership of these haplotypes relates to the risk of CVD and
mortality. Time-to-event analysis was performed to estimate
the risk of CVD for females carrying the risk haplotype
CTCTAG without the protective haplotype CCCTAA. The
females carrying the risk haplotype CTCTAG, but without the
protective haplotype CCCTAA, had the highest CVD risk
when compared to any other group of haplotype carriers, this
risk being 2.8-fold (HR 2.77; 95% CI 1.50–5.13; p¼0.001). This
result remained signiﬁcant after correcting for multiple
testing: In permutation analysis, the critical p-value for 5%
signiﬁcance level was 0.003.
Finally, we tested whether the sequence variants of USF1
have an effect on lipids, body mass index (BMI), or waist-to-
hip circumference ratio, the traits characteristic of FCHL and
other conditions with earlier-reported associations with USF1
and known contributors to the CVD risk. The obtained
results support previous ﬁndings of the best association
observed for lipid values in males, and are summarized in
Tables 5 and S1.
When males and females were analyzed together, signiﬁ-
cant associations among incident CVD cases were seen with
higher levels of cholesterol and non-high-density lipoprotein
(HDL) cholesterol with the C-allele of rs2073658 (p¼0.02 and
p ¼ 0.02 for cholesterol and non-HDL cholesterol, respec-
tively), C-allele of rs2516839 (p , 0.0001 and p ¼ 0.0001), and
G-allele of rs1556259 (p ¼ 0.01 and p ¼ 0.03). Among the
subcohort free of CVD, the G-allele of rs2774276 was
associated with higher waist-to-hip ratios (p ¼ 0.009). For all
these pooled analyses the critical p-value for 5% signiﬁcance
level was 0.006.
Discussion
We previously established the association of the USF1 gene
with FCHL in a set of rare Finnish families with multiple
dyslipidemic individuals [2], known to be predisposed to a
signiﬁcantly increased risk for CVD. Here we show that allelic
variants of the USF1 gene have an impact on CVD risk also at
the population level, a ﬁnding rarely established for any
complex disease gene so far.
The biological importance of the USF1 gene has been
implied in several studies reporting an association between
USF1 and disorders of lipid and glucose metabolism, mostly
in study samples ascertained for these traits. Following the
ﬁrst association report for USF1 with FCHL in Finnish FCHL
families [2], the association was replicated in Mexican FCHL
families [3]. Further, in Utah pedigrees ascertained for early
death due to coronary heart disease (CHD), early stroke, or
early-onset of hypertension, USF1 was found to be associated
with FCHL-related lipid traits, especially in males [8]. USF1
has also been implicated in the etiology of metabolic
syndrome and type II diabetes [4], common conditions
predisposing to premature CVD. Additional studies show
variants of USF1 as being associated with features of glucose
and lipid homeostasis in healthy young men [9] and increased
adipocyte lipolysis in healthy obese women [7]. Although
multiple studies have provided evidence of the role of USF1
in CVD-associated dyslipidemias, the direct contribution of
the USF1 gene to CVD and mortality at the population level
has not been assessed.
Here we prospectively followed up two distinct cohorts
representative of the general Finnish population of the study
areas. Using Cox proportional hazards regression analysis
measuring time-to-event, we found a female-speciﬁc associ-
ation of two USF1 htSNPs, deﬁning a ‘‘risk allele’’ of USF1,
with both CVD and all-cause mortality. We also tentatively
identiﬁed a ‘‘protective’’ allele for this gene.
The USF1 risk allele identiﬁed here for the cohort females
differs from the risk allele segregating in FCHL families. In 60
Finnish FCHL families the risk was associated with the
common allele of rs2073658 [2], whereas in the present study
the SNP haplotype CTCTAG, carrying the minor allele of
rs2073658, was associated with a risk effect. However, our
original FCHL study did not address the female risk allele in
any detail, since the most signiﬁcant association was observed
in males with high triglycerides. We performed a simple
analysis of the original FCHL data, choosing families (32 out
of 60) in which at least 50% of those affected were female.
Among these affected FCHL females the frequency of the
minor allele of rs2073658 (haplotype CTCTAG seen in
FINRISK females) was higher than among the unaffected
females of those families (45% versus 38%, respectively), thus
supporting our ﬁndings. In addition, the frequency of the
Figure 2. The Haplotype Structure in the USF1 Gene Locus
The six genotyped SNPs from the USF1 gene locus resulted in five
common haplotypes. The haplotype frequencies were calculated for the
two FINRISK subcohorts combined.
DOI: 10.1371/journal.pgen.0020069.g002
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USF1 in a Prospective Study‘‘protective’’ FINRISK haplotype CCCTAA was 23% in
affected females of those families and 30% in unaffected
females. Thus the obtained results of the ‘‘risk allele’’ of USF1
in these two studies are comparable, although we recognize
that the ascertainment strategy for the FCHL families results
in a biased selection of population alleles and complicates the
estimation of any sex-speciﬁc effect in these rare families.
Many previous studies have found the inﬂuence of USF1 to be
more prominent among males [2,8], or have studied only
males [9], whereas here we saw the most signiﬁcant evidence
of association among females. The lack of association among
males at the population level in our cohorts could be
explained by environmental covariates. CVD events are more
common in males, most probably due to clustering of
numerous lifestyle risk factors, including smoking, obesity,
and high blood pressure, this increasing the environmental
‘‘noise’’ and complicating genetic analyses in males compared
to females.
The association of USF1 with CVD in females of two
distinct population cohorts supports the real involvement of
USF1 in CVD risk. Moreover, the trends of the hazard ratios
for the risk-associated alleles of USF1 were the same in both
FINRISK cohorts, and the same risk alleles of USF1 were
associated both with CVD events and all-cause mortality
among females, further supporting their signiﬁcance. Finally,
correcting for multiple testing with permutations providing a
more stringent signiﬁcance threshold for the original p-values
still retained a signiﬁcant association between USF1 variation
and the risk of CVD and mortality among females.
In the association analyses of SNPs with lipid parameters,
we observed USF1 htSNPs to strongly associate with plasma
cholesterol levels and non-HDL cholesterol especially among
the male CVD cases. These ﬁndings conﬁrm prior reports
that USF1 variants contribute to differences in lipid proﬁles
[2–4,7–9]. However, no associations with traditional risk
factors were obtained that would explain the increased risk
of CVD and mortality among female carriers of USF1 risk
alleles. The question remains whether the impact of USF1 on
lipid parameters among females is as powerful as among
males, or if the gene variants have alternative ways of
increasing the CVD risk—for example, through inﬂamma-
tion-related pathways.
As noted previously, the strong LD of the USF1 locus
extends the critical FCHL region to 46 kb in Finnish FCHL
families [2]. This DNA region may harbor additional variants
that represent true functional variants that affect CVD risk.
Sequencing of the complete region in sufﬁciently large study
samples would shed light on the risk-increasing variants of
USF1, and would enable the detailed functional studies
needed to establish their role. So far, functional data exist
only for the most signiﬁcantly associated SNP of the original
FCHL study, rs2073658 [1].
In conclusion, here we have shown that the risk effect of a
gene identiﬁed in a rare set of FCHL families who are at
exceptionally high risk for cardiovascular events can be
conﬁrmed in a population-based prospective follow-up study.
We observed one ‘‘risk’’ and one ‘‘protective’’ allelic
haplotype of USF1 that signiﬁcantly contribute to the risk
for CVD and all-cause mortality among females. To evaluate
the signiﬁcance of these results obtained in the Finnish
cohorts for CVD risk more globally, other populations need
to be analyzed. Still, this study demonstrates, to our knowl-
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USF1 in a Prospective Studyedge for the ﬁrst time, that USF1 gene variation may have a
long-term predictive effect on CVD risk in females, and thus
adds another piece of proof to the accumulating evidence
that the gene plays an important role in the progression of
CVD.
Materials and Methods
Study populations. Our population cohorts were collected via the
FINRISK [5] studies. FINRISK surveys are carried out every 5 y and
are designed to assess the prevalence and risk factors of cardiovas-
cular diseases in Finland. The FINRISK-92 study contacted a random
sample of 8,000 persons aged 25–64 y from four geographical areas of
Finland (Helsinki region, southwestern Finland, North Karelia, and
Kuopio region) as part of the WHO MONICA Project (Multinational
Monitoring of Trends and Determinants in Cardiovascular Disease,
an international study conducted under the auspices of the World
Health Organization) [10]. The persons were selected through
random sampling of the population, stratiﬁed by sex, area, and 10-y
age group (25–34, 35–44, 45–54, and 55–64 y). The protocol was as
established by the WHO MONICA [10] Project.
The FINRISK-97 study contacted 10,000 persons from the same
regions, selected using the same sampling procedure and using the
same protocols as the FINRISK-92 study, but including also the
province of Oulu. In addition, 250 females and 500 males aged 65–74 y
were included from two of the areas. At the beginning of the follow-up
period, the overall response rates covering participants with all
required information for the genetic study were 71% for males and
79% for females in the FINRISK-92study, and 68% for males and 74%
for females in the FINRISK-97 study, resulting in a total of 14,140
participants out of the 19,500 in the original sample (Figure 1). No
overlap exists between the FINRISK-92 and the FINRISK-97 cohorts.
The FINRISK-92 and FINRISK-97 studies were approved by the
Ethical Committee of the National Public Health Institute, the
participants gave an informed consent, and the principles of the
Helsinki Declaration were followed.
Both FINRISK-92 and 97 cohorts are participating in the ongoing
MORGAM Project (http://www.ktl.ﬁ/morgam) [11], a multinational
collaborative study.
The follow-up period for participants of FINRISK-92 lasted from
spring 1992 until the end of December 2001, a total of 10 y. In
FINRISK-97 the participants were followed up for 7 y, from 1997
until the end of December 2003. More detailed information about the
FINRISK cohorts and the follow-up procedures can be found in the
cohort descriptions of the MORGAM Project (http://www.ktl.ﬁ/
publications/morgam/cohorts).
Baseline examination and follow-up of FINRISK studies. At the
baseline, all participants were asked to ﬁll in a self-administered
questionnaire and were physically examined. The physical examina-
tion included blood pressure, waist, hip, weight, and height measure-
ments. The self-administered questionnaire asked respondents for
information on the most established environmental cardiovascular
risk factors, e.g., demographic variables, history of CVD, history of
diabetes, medication, smoking, and additional lifestyle and dietary
habits. Blood was collected in a ‘‘semifasting’’ state, i.e., the
participants were instructed to fast for 4 h and to avoid fatty meals
earlier during the day. Serum total cholesterol, HDL cholesterol, and
triglyceride levels were measured. Whole blood was stored at  20 8C
for DNA extraction.
Case-cohort design. We used a case-cohort design [12], in which
DNA was genotyped only for stratiﬁed random samples—subco-
horts—of the FINRISK-92 and  97 cohorts, and for participants
experiencing death, coronary event, or stroke during the follow-up
periods (Figure 1). In addition, DNA of participants experiencing
venous thromboembolic event or reporting history of CVD at the
baseline examination was genotyped (http://www.ktl.ﬁ/publications/
morgam/cohorts); however, venous thromboembolism and baseline
CVD were not analyzed as endpoints in our genetic study. Further,
participants with prevalent CVD were excluded from our genetic
analyses, except when analyzing all-cause mortality, for which all
subcohort members and all deaths were included regardless of their
CVD history. Information about coronary and stroke events during
the follow-up periods was obtained from several sources: speciﬁc
myocardial infarction and stroke registers (FINAMI [13] and
FINSTROKE [14]) complemented with record linkage of the study
data with the National Causes of Death Register and the National
Hospital Discharge Register. These country-wide, computerized
registers cover every death of Finnish citizens and every hospital-
ization in Finland, and thus the coverage of follow-up for
symptomatic CVD events was almost 100%. In the National Causes
of Death Register International Classiﬁcation of Diseases (ICD)-9
codes 410–414 and 798, and ICD-10 codes I21–I25, I46, R96, R98 and
R99 were taken as coronary deaths. ICD-9 codes 433 (excluding
4330X, 4331X, 4339X of the Finnish modiﬁcation of ICD-9; see http://
www.ktl.ﬁ/publications/morgam/cohorts) and 434 (excluding 4349X),
and ICD-10 code I63, were taken as ischemic stroke deaths. In the
National Hospital Discharge Register ICD-9 codes 410–411, and ICD-
10 codes I21–I22 and I20.0, were taken as nonfatal coronary events;
and ICD-9 codes 433 (excluding 4330X, 4331X, 4339X) and 434
(excluding 4349X), and ICD-10 code I63, were taken as nonfatal
ischemic stroke events. ICD-9 was used in Finland until 31 December
1995, and ICD-10 after that. The combination of FINAMI register and
the National Hospital Discharge Register was also used to identify
revascularization procedures (CABG and PTCA) during the follow-up
period. The validity of cardiovascular diagnoses in the Finnish Causes
of Death Register and the Hospital Discharge Register has been
documented in several publications [15–17].
Unique Finnish social security numbers of the participants were
compared between the two cohorts, and participants already enrolled
in the FINRISK-92 cohort were excluded from the FINRISK-97
cohort.
In the present study, incident CVD and all-cause mortality were
analyzed as endpoints. Incident CVD cases included the persons
without prevalent CVD at baseline who suffered a fatal or nonfatal
ischemic stroke event, or fatal or nonfatal coronary event during the
follow-up period (Figure 1 and Table 1). The number of main study
endpoints was used as reference to determine the size of the random
subcohorts to be selected from the original population cohorts and
age was controlled through sampling weights (http://www.ktl.ﬁ/
publications/morgam/manual/contents.htm) (Figure 1). The selection
of the subcohort members was independent of the selection of cases,
thus of the 374 male and 154 female incident CVD cases, 72 were also
part of the subcohorts. Altogether 610 persons (180 females and 430
males) died during the follow-ups of the two cohorts. Table 2 shows
the baseline characteristics of the incident CVD cases and subcohort
members free of CVD.
DNA extraction. DNA was extracted from EDTA-treated whole-
blood samples using a standard phenol-chloroform method modiﬁed
from Vandenplas et al. [18]. DNA of 23 FINRISK-92 samples was
extracted by a salt-precipitation method.
Markers. To capture the allelic diversity of the 5.69 kb USF1 gene
in the FINRISK-92 and 97 cohorts, we genotyped six htSNPs (Figure
2). Rs2073658 in intron 7 of the USF1 gene was the most signiﬁcantly
associated SNP in our previous FCHL study [2]. Additional htSNPs
were selected using the SeattleSNPs Variation Discovery Resource [6].
All common (average minor allele frequency . 4%) LD select bins for
European descent were covered with our SNP selection.
Rs2516839 and rs1556259 were included in our family-based study
[2], but showed no association with FCHL. Rs10908821 is located in an
intron of the F11 receptor gene (F11R), 2.23 kb downstream from
rs2073658. Rs2774276 resides in intron 5 of USF1, 0.95 kb upstream of
rs2073658. SNP rs2774279 results in a synonymous amino acid
substitution (874 R/R) in an exon of a predicted gene LOC257106,
and is located 2.90 kb upstream from rs1556259.
Genotyping. Most of the genotyping was performed using the
MassARRAY System(Sequenom,San Diego,California,UnitedStates),
with a protocol described elsewhere [19]. SNPs rs2073658, rs2516839,
and rs2774279 were genotyped in the FINRISK-92 study sample using
allele-speciﬁc primer extension on microarrays with a protocol
described elsewhere [19,20]. For MassARRAY System genotyping, 81
low-yield DNA samples of the FINRISK-92 study sample and 19 low-
yield DNA samples of the FINRISK-97 study sample were ﬁrst
ampliﬁed in replicates using GenomePhi DNA ampliﬁcation kit (GE
Healthcare UK, Buckinghamshire, England) as speciﬁed in the
manufacturer’s instructions and genotyped as described [19].
The staff in the genotyping laboratory were blinded to sex and
disease status of participants. To control for sample mix-ups, all
samples were genotyped for sex, and the data were compared to the
sex of participants as recorded in the database. Plate-speciﬁc
duplicates and water samples were used to control for plate-handling
errors. Of the samples genotyped, 5% were blinded duplicates. The
USF1 marker genotypes of the blinded duplicate pairs were
compared after genotyping and were all found to be consistent.
The success rate of genotyping was 98% for SNP rs2774276 and 97%
for all other SNPs.
Haplotype estimations. LD and haplotype block analysis and
haplotype population frequency estimations were performed with
Haploview version 3.2 [21] using the two FINRISK subcohorts
PLoS Genetics | www.plosgenetics.org May 2006 | Volume 2 | Issue 5 | e69 0679
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were excluded from the analysis, thus 782 individuals were used in the
haplotype estimations.
Data analyses. Allele and genotype frequencies were determined
from the data, and deviation from the Hardy-Weinberg equilibrium
was tested using Pearson’s chi-square. Pearson’s chi-square statistic
was used to compare allele frequencies between incident CVD cases
and subcohorts free of CVD.
A weighted Cox proportional hazards model, modiﬁed to account
for the case-cohort sampling design, was used for risk analyses with
the variance correction based on the published literature using SAS
PHREG procedure [12,22,23]. Age represented the time measure in
the models. Covariates known to associate with CVD (age, sex,
hypertension, smoking, diabetes, total cholesterol to HDL ratio, and
BMI) were included in multivariate models as potential confounders.
When analyzing CVD, individuals with prevalent CVD at the baseline
were excluded from analyses. Analyses were stratiﬁed for eastern and
western Finland, and the cohort was used as a covariate. Carriership
of the minor and major allele was analyzed for each SNP, except for
the two SNPs with lowest minor allele frequencies (rs10908821 and
rs1556259), for which only the carriership of the minor allele was used
in the analysis due to the low number of individuals homozygous for
the minor allele.
To determine the relation between the USF1 htSNPs and several
baseline variables, we computed age-, sex-, geographical area-, and
cohort-adjusted mean values for SNP allele groups and tested the
difference with analyses of covariance implemented in the SAS
‘‘PROC GLM’’ procedure. Before analyses, the variables HDL and
triglyceride were log-transformed to correct them to be normally
distributed. Mean values of the variables are displayed as crude data
on Tables 5 and S1. Individuals deviating 6 4 standard deviations
(SD) from the mean were excluded as outliers from the analyses.
Further, the analyses were conducted using subcohort members free
of CVD at baseline and incident CVD cases.
To evaluate the signiﬁcance of our ﬁndings, we permuted the
genotype while retaining the phenotype data within sex/cohort
groups, and repeated the same analyses that were performed with
the actual dataset, recording the minimum p-value observed. We
repeated this procedure 1,000 times and took the ﬁfth percentile of
these minimum p-values as the new multiple-testing corrected
threshold for the p-values obtained with the original data.
Statistical analyses were carried out using the SAS statistical
software (versions 8.2. and 9.1 for Windows) (SAS OnlineDoc, Version
8, 1999; SAS Institute, Cary, North Carolina, United States).
Supporting Information
Table S1. Association between USF1 SNP Alleles and Lipids, BMI, and
Waist-To-Hip Ratio in FINRISK Subcohort Males and Females
Found at DOI: 10.1371/journal.pgen.0020069.st001 (27 KB XLS).
Accession Numbers
The Entrez Gene (http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?db¼gene) accession numbers for USF1 and F11R are 7391 and
50848, respectively. The online Mendelian Inheritance in Man
(OMIM) http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db¼omim) ac-
cession numbers for FCHL, metabolic syndrome, and type II diabetes
are 144250, 605552, and 125853, respectively.
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